Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world irinotecan hydrochloride liposome injection II in pancreatic cancer
ChiCTR2600129421Phase 4Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Aug 2026
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of liposomal irinotecan in pancreatic adenocarcinoma (PDAC), sponsored by Ruijin Hospital. Primary endpoint: Adverse events. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
liposomal irinotecan
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ChiCTR2600129421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600129421.